Research Topics
| P CassanoSummaryAffiliation: Massachusetts General Hospital Country: USA Publications
| Collaborators
|
Detail Information
Publications
Major depressive disorder with psychosis-like symptoms among LatinosPaolo Cassano
Department of Psychiatry, Massachusetts General Hospital, 1 Bowdoin Square, Sixth Floor, Boston, MA 02114, USA
Psychiatr Serv 63:482-7. 2012....
Ropinirole in treatment-resistant depression: a 16-week pilot studyPaolo Cassano
Depression Clinical and Research Program, Massachusetts General Hospital, Boston 02114, USA
Can J Psychiatry 50:357-60. 2005..The study aimed to assess the antidepressant efficacy and tolerability of adjunctive ropinirole in outpatients with treatment-resistant depression (TRD)...- Antidepressant response and well-being in pre-, peri- and postmenopausal women with major depressive disorder treated with fluoxetinePaolo Cassano
The Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
Psychother Psychosom 74:362-5. 2005..We assessed the impact of menopausal status on treatment response and well-being in a cohort of outpatient women with major depressive disorder (DSM-III-R criteria), who received treatment with fluoxetine (20 mg/day for 8 weeks)... - Pramipexole in treatment-resistant depression: an extended follow-upPaolo Cassano
Department of Psychiatry, Neurobiology, Pharmacology and Biotechnology, University of Pisa, Pisa, Italy
Depress Anxiety 20:131-8. 2004..Pramipexole augmentation of antidepressant treatment was relatively safe and presumably effective in the long-term course of treatment resistant depression... - Sex- and age-related differences in major depressive disorder with comorbid anxiety treated with fluoxetineP Cassano
Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, Boston, MA 02114, U S A
Arch Womens Ment Health 7:167-71. 2004..To examine sex- and age-related differences of treatment outcome in a cohort of outpatients with major depressive disorder (MDD), with and without comorbid anxiety, treated with fluoxetine... - Tolerability issues during long-term treatment with antidepressantsPaolo Cassano
Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Ann Clin Psychiatry 16:15-25. 2004..Therefore, clinicians are likely to prefer them in usual practice, especially among patients requiring maintenance treatment. The present review focuses on management of long-term side effects... - Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorderLee S Cohen
Perinatal and Reproductive Psychiatry Clinical Research Program, Massachusetts General Hospital MGH, Harvard Medical School, Boston, MA 02114, USA
J Clin Psychopharmacol 24:540-3. 2004..05 for all comparisons, Wilcoxon tests). Intermittent treatment was well tolerated. This preliminary report suggests that premenstrual use of venlafaxine is an efficacious and well-tolerated treatment for premenstrual dysphoric disorder... - Pramipexole in treatment-resistant depression: a 16-week naturalistic studyLorenzo Lattanzi
Department of Psychiatry, Neurobiology, Pharmacology and Biotechnologies, University of Pisa, Italy
Bipolar Disord 4:307-14. 2002..To assess the antidepressant efficacy and tolerability of adjunctive pramipexole, a D2-D3 dopamine agonist, in patients with drug-resistant depression... - Major depressive disorder with anger attacks and subcortical MRI white matter hyperintensitiesDan V Iosifescu
Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
J Nerv Ment Dis 195:175-8. 2007..Atypical and melancholic MDD subtypes were not significantly associated with brain WMH. In conclusion, subcortical brain vascular lesions may be more prevalent or severe in MDD with anger attacks... - Treatment of depression with comorbid anxiety disorders: differential efficacy of paroxetine versus moclobemideStefano Pini
Department of Psychiatry, Neurobiology, Pharmacology and Biotechnology, University of Pisa, Pisa, Italy
Int Clin Psychopharmacol 18:15-21. 2003..However, in the subgroup with comorbid panic disorder, paroxetine is more effective than moclobemide in reducing both depressive and anxiety symptoms... - The psychotic spectrum: validity and reliability of the Structured Clinical Interview for the Psychotic SpectrumA Sbrana
Department of Psychiatry, University of Pisa, Via Roma 67, 56127 Pisa, Italy
Schizophr Res 75:375-87. 2005..The SCI-PSY significantly discriminated subjects with any psychiatric diagnosis from controls and subjects with from those without psychotic disorders. The hypothesized structure of the instrument was confirmed empirically... 
Patterns of structural MRI abnormalities in deficit and nondeficit schizophreniaSilvana Galderisi
Department of Psychiatry, University of Naples SUN, Largo Madonna delle Grazie, 80138 Naples, Italy
Schizophr Bull 34:393-401. 2008..These findings do not support the hypothesis that DS is the extreme end of a severity continuum within schizophrenia...- Catechol-O-methyltransferase Val158Met polymorphism in schizophrenia: associations with cognitive and motor impairmentSilvana Galderisi
Department of Psychiatry, University of Naples SUN, Naples, Italy
Neuropsychobiology 52:83-9. 2005..These results support the hypothesis that the COMT Val(158)Met polymorphism influences executive functions in schizophrenia and the neuromotor performance in the deficit subtype only... - Depression and renal diseaseEliana Tossani
Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Semin Dial 18:73-81. 2005..Screening for CYP isoenzyme interactions with current medications is also recommended before starting antidepressant treatment... - COMT Val(158)Met and BDNF C(270)T polymorphisms in schizophrenia: a case-control studySilvana Galderisi
Department of Psychiatry, University of Naples SUN, Largo Madonna delle Grazie 1, 80138 Naples, Italy
Schizophr Res 73:27-30. 2005..These results do not support the hypothesis that the COMT Val(158)Met or BDNF C(270)T gene polymorphisms are associated with liability to schizophrenia... - Depression and public health: an overviewPaolo Cassano
Depression Clinical and Research Program, Massachusetts General Hospital, 15 Parkman Street-ACC 812, Boston, MA 02114, USA
J Psychosom Res 53:849-57. 2002..Programs aimed at improving patient follow-up and the coordination of the primary care intervention with that of specialists have been found to improve patient outcomes and to be cost effective... - Substance use disorder comorbidity in major depressive disorder: a confirmatory analysis of the STAR*D cohortLori L Davis
VA Medical Center, Tuscaloosa, AL 35404, USA
Am J Addict 15:278-85. 2006..048 to <0.0001). They were also less likely to be Hispanic and endorse general medical comorbidities (p = 0.006 and 0.002, respectively)... - Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of lifeClaudio N Soares
Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada
Menopause 13:780-6. 2006..To examine the efficacy and tolerability of escitalopram (ESCIT) compared to estrogen and progestogen therapy (EPT) for the treatment of symptomatic peri- and postmenopausal women... - Substance use disorder comorbidity in major depressive disorder: an exploratory analysis of the Sequenced Treatment Alternatives to Relieve Depression cohortLori L Davis
VA Medical Center, Tuscaloosa, AL 35404, USA
Compr Psychiatry 46:81-9. 2005..In conclusion, gender, marital status, age of onset of major depression, functional impairment, and suicide risk factors differ in depressed patients with concurrent SUD symptoms compared to those without SUD comorbidity...